AL101

TargetSORT1

Modalitymonoclonal antibody

IndicationNeurodegenerative diseases

PhasePhase 1 (Completed)

PartnerGSK

Trial IDNCT04111666

Registry statusCOMPLETEDVerified 2026-10-05

Notes

AL101 blocks the sortilin receptor (SORT1) to increase circulating levels of progranulin (GRN), a critical lysosomal and microglial regulatory protein.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: October 5, 2026